Korea to cover Pfizer's Xalkori; Botox wins another label expansion; Merck CEO Frazier elected PhRMA board chairman;

@FiercePharma: Shanghai Haohai Biological plans Hong Kong IPO to raise $263M. FiercePharmaAsia story | Follow @FiercePharma

@EricPFierce: ICYMI: 275 GSK jobs at risk with consumer health move from Pittsburgh. Some will get offers in New Jersey. Article | Follow @EricPFierce

@CarlyHFierce: ICYMI: Bad news, Teva--Sandoz has an FDA nod for generic Copaxone. But when will it launch? Story | Follow @CarlyHFierce

> Korea's national health insurance will cover Pfizer ($PFE) cancer drug Xalkori. More

> Massachusetts' highest court has upheld a $63 million verdict against Johnson & Johnson ($JNJ) over claims the company failed to properly warn consumers about the dangers of Children's Motrin. More

> Actavis' ($ACT) Botox has won FDA approval for the treatment of upper limb spasticity in adults. Release

> Pfizer is joining New York Gov. Andrew Cuomo's visit to Cuba. Report

> Merck ($MRK) CEO Ken Frazier has been elected chairman of the Board of the Pharmaceutical Research and Manufacturers of America (PhRMA). More

> India's Glenmark Pharmaceuticals is raising $151 million through a preferential allotment to Singapore government-owned investment firm Temasek. Report

Medical Device News

@FierceMedDev: ICYMI: NEA-backed Cartiva raises $6M after a recent FDA nod, as it heads into a PMA review. Story | Follow @FierceMedDev

@VarunSaxena2: UPDATED: HeartWare device meets trial endpoint, but stroke data a big concern. ICYMI | Follow @VarunSaxena2

@EmilyWFierce: VisualDx sees big future for mobile diagnostic tool. FierceDiagnostics report | Follow @EmilyWFierce

> FDA approves first near vision correcting implant that doesn't require cataract surgery. More

> Endo settles more than 350 vaginal mesh suits. Article

> Report: Patterson Companies looking to shed rehab supply business. Story

Biotech News

@FierceBiotech: Roche bets $555M on an Indian biotech's immuno-oncology drug. News | Follow @FierceBiotech

@JohnCFierce: What's driving the massive social media campaign for Genervon's ALS drug? (Exaggerated claims and a false assumption). Editor's corner | Follow @JohnCFierce

> Biotech guru Neil Woodford lands $1.2B for new tech fund. Report

> Data in hand, Merck shoots for Keytruda approval for lung cancer. Item

> Ampio routed as lead osteoarthritis drug flunks a PhIII test. News

> Novartis' new CAR-T hopeful looks safe in an early solid tumor study. Article

Animal Health News

> Fears of dog flu epidemic spread as questions arise about vaccine's effectiveness. News

> UN restrictions on narcotic ketamine would impede veterinary practices, trade group argues. More

> FDA coordinates with pharma to address IV fluid shortage. Item

> Cannabis biscuits sell out as lobbyists push medical marijuana rights for pets. Story

> Nexvet regroups as key study on lead dog drug shows 'low probability' of success. Article

Biotech IT News

> Sanofi sues drug information startup over side effect info. Item

> Biopharma puts better use of existing data at top of R&D wish list. More

> Apple, IBM team up for Watson-fueled assault on health research. Article

> California starts statewide precision medicine initiative with Atul Butte at the helm. Story

> PatientsLikeMe adds AstraZeneca to growing list of big-name clients. Report

And Finally... Having both depression and Type 2 diabetes may increase patients' risk of developing dementia, new research shows. More

Suggested Articles

Former Indivior CEO Shaun Thaxter will face six months in federal prison for his role in misleading government officials on the dangers of Suboxone.

As of Friday after local time, 36 people have died in Korea after getting flu shots provided by at least seven companies, including Sanofi.

Two prominent pneumococcal vaccines from Merck and Pfizer are running low in Europe in a possible ill omen for the coming winter: report.